Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Childress

Podiatrist Louisville, KY Doctor of Podiatric Medicine

NPI 1013094978 CMS profile 571

3 Audubon Plaza Dr, Suite 320, Louisville, KY 40217

Open in the dashboard

General payments

$283,198

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$825,011

2 holdings reported · through program year 2025

Through program year 2025, Thomas Childress of Louisville, KY is reported in the CMS Open Payments database as having received $283,198 across 164 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $825,011 across 2 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $758 11
2024 General $800 17
2023 General $2,879 48
2022 General $587 24
2021 General $851 26
2020 General $276,536 30
2019 General $787 8
2020 Ownership $275,011 1
2019 Ownership $550,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Childress
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Thomas Childress were reported at $758. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Thomas Childress Podiatrist median Middle half National median
2019 $787 $196 $72–$601 $163
2020 $276,536 $118 $38–$335 $114
2021 $851 $169 $57–$573 $132
2022 $587 $220 $74–$782 $149
2023 $2,879 $208 $71–$635 $160
2024 $800 $237 $87–$681 $164
2025 $758 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paragon 28, Inc. $274,989 1 payment
  2. Fusion Orthopedics USA, LLC $1,257 3 payments
  3. Stryker Corporation $1,150 13 payments
  4. Smith+Nephew, Inc. $1,052 79 payments
  5. Integra LifeSciences Corporation $715 7 payments
  6. Alpha Orthopedic Systems $640 3 payments
  7. Misonix Inc $447 19 payments
  8. Bioventus LLC $351 4 payments
  9. Baxter Healthcare $246 2 payments
  10. Kerecis Limited $184 2 payments
  11. Other $2,167 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $274,989 1 payment
  2. Food and Beverage $6,608 160 payments
  3. Travel and Lodging $1,146 2 payments
  4. Education $455 1 payment
Products named General payments · program years 2019–2025
  1. STRAVIX $865 60 payments
  2. Integra Recon-Skin And Wound $488 5 payments
  3. Integra Recon-Skin And Wound $488 5 payments
  4. PRIMATRIX $488 5 payments
  5. Integra Recon-Skin And Wound $488 5 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $488 5 payments
  7. GRAFIX PL $416 22 payments
  8. GRAFIX $346 16 payments
  9. PROPHECY $304 3 payments
  10. OASIS $275 11 payments
  11. Other $7,363 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

754

Median for Podiatry: 160

Drug cost

$8,183

Median for Podiatry: $2,368

Branded share of claims

8.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 265 $3,179
Diclofenac Sodium Generic 155 $1,275
Ketoconazole Generic 51 $1,074
Cephalexin Generic 30 $705
Terbinafine Hcl Generic 84 $569
Pregabalin Generic 33 $411
Mometasone Furoate Generic 22 $339
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 48 $327
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $184
Meloxicam Generic 51 $121

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$106,775

Of which drugs: $18,580

Medicare patients

299

Average age 75

Services billed

1,554

156 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 51%
Ischemic heart disease 41%
Chronic kidney disease 30%
Atrial fibrillation 25%
Heart failure 24%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 148 $107

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record